4 - CITIUS ONCOLOGY, INC. (0001851484) (Issuer)

4 - CITIUS ONCOLOGY, INC. (0001851484) (Issuer)

4 - CITIUS ONCOLOGY, INC. (0001851484) (Issuer)

4 - CITIUS ONCOLOGY, INC. (0001851484) (Issuer)

4 - CITIUS ONCOLOGY, INC. (0001851484) (Issuer)

4 - CITIUS ONCOLOGY, INC. (0001851484) (Issuer)

4 - CITIUS ONCOLOGY, INC. (0001851484) (Issuer)

4 - CITIUS ONCOLOGY, INC. (0001851484) (Issuer)

3 - CITIUS ONCOLOGY, INC. (0001851484) (Issuer)

3 - CITIUS ONCOLOGY, INC. (0001851484) (Issuer)

TenX Keane shareholders voted to approve the previously announced merger with Citius Oncology at an extraordinary general meeting held on August 2, 2024 Post-merger company expected to trade on Nasdaq as Citius Oncology, Inc. (CTOR) New York, NY, Aug. 09, 2024 (GLOBE NEWSWIRE) -- On August 7, 2024, TenX Keane Acquisition (NASDAQ:TENKU, TENK, TENKR))) ("TenX"), a publicly traded special purpose acquisition company, was notified by The Nasdaq Stock Market that trading in TenX's securities had been halted for "additional information requested" from the company. The trading halt was imposed following volatility in the trading price and volume of TenX's securities on Wednesday, August 7, 202

TenX Keane shareholders voted to approve the previously announced merger with Citius Oncology at an extraordinary general meeting held on August 2, 2024 Post-merger company expected to trade on Nasdaq as Citius Oncology, Inc. Transaction expected to support commercialization of LYMPHIR, if approved, and exploration of additional oncology assets New York, NY, Aug. 05, 2024 (GLOBE NEWSWIRE) -- TenX Keane Acquisition (NASDAQ:TENKU, TENK, TENKR))) (the "TenX"), a publicly traded special purpose acquisition company, today announced that on August 2, 2024, at the extraordinary general meeting, its shareholders voted to approve the previously announced business combination with the wholly own

Citius Pharmaceuticals to receive 65.6 million shares of TenX Keane, which will be renamed Citius Oncology, Inc. Citius Pharmaceuticals to retain approximately 90% majority control post transaction    Post-merger company expected to trade on Nasdaq as Citius Oncology, Inc. Transaction expected to support commercialization of LYMPHIR, if approved, and exploration of additional oncology assets CRANFORD, N.J., Aug. 5, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (NASDAQ:CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that shareholders of TenX Keane

Multiple catalysts for potentially transformative assets in second half of 2024Strong momentum expected from positive topline results of Phase 3 Mino-Lok® trial, commercialization of LYMPHIR™ if approvedFirst-and-only advantage for Mino-Lok with no current FDA-approved or investigational products; LYMPHIR expected to be additive to current treatment options with mechanism of action supporting market advantageFinancial platform and pending oncology spin-off support pipeline development and investment in long-term growthClinical and operational achievements offer powerful levers for value creationNational Sales Director onboarded to recruit and lead the sales organization in preparation for an

New York, NY, Jan. 10, 2024 (GLOBE NEWSWIRE) -- TenX Keane Acquisition (NASDAQ:TENKU, TENK, TENKR))) (the "Company"), announced today that if the proposal to amend the Company's Amended and Restated Memorandum and Articles of Association, which provides that the Company may elect to extend the date by which the Company has to consummate a business combination for a total of eight (8) times, as follow: (i) one (1) time for an additional three (3) months from January 18, 2024 to April 18, 2024, and subsequently (iii) seven (7) times for an additional one (1) month each time from April 18, 2024 to November 18, 2024 (the "Extension Amendment Proposal"), is approved at the Company's previously

Citius Pharmaceuticals, Inc. to receive $675 million in equity of Citius Oncology, Inc. and retain approximately 90% majority control in publicly listed Citius Oncology, Inc. post transaction Transaction anticipated to close in the first half of 2024 CRANFORD, N.J. and NEW YORK, N.Y., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (NASDAQ:CTXR), a biopharmaceutical company developing and commercializing first-in-class critical care products, and TenX Keane Acquisition ("TenX") (NASDAQ:TENKU), a publicly traded special purpose acquisition company (SPAC), today announced that they have entered into a definitive agreement, dated Oct

New York, NY, Oct. 18, 2023 (GLOBE NEWSWIRE) -- TenX Keane Acquisition (the "Company") (NASDAQ:TENKU) today announced that, in order to extend the date by which the Company must complete its initial business combination from October 18, 2023 to January 18, 2024, the Company has deposited into its trust account (the "Trust Account") an aggregate of $660,000 (the "Extension Fee"), representing $0.10 per public share of the Company. The payment for such Extension Fee was made by 10XYZ Holdings LP, the sponsor of the Company (the "Sponsor"), which was evidenced by an unsecured promissory note issued by the Company to the Sponsor. This press release shall not constitute an offer to sell or a

New York, NY, July 18, 2023 (GLOBE NEWSWIRE) -- TenX Keane Acquisition (the "Company") (NASDAQ:TENKU) today announced that, in order to extend the date by which the Company must complete its initial business combination from July 18, 2023 to October 18, 2023, the Company has deposited into its trust account (the "Trust Account") an aggregate of $660,000 (the "Extension Fee"), representing $0.10 per public share of the Company. The payment for such Extension Fee was made by 10XYZ Holdings LP, the sponsor of the Company (the "Sponsor"), which was evidenced by an unsecured promissory note issued by the Company to the Sponsor. This press release shall not constitute an offer to sell or a so

SC 13D/A - CITIUS ONCOLOGY, INC. (0001851484) (Subject)

SC 13G/A - TenX Keane Acquisition (0001851484) (Subject)

SC 13G - TenX Keane Acquisition (0001851484) (Subject)

SC 13G - TenX Keane Acquisition (0001851484) (Subject)

SC 13G - TenX Keane Acquisition (0001851484) (Subject)

SC 13G/A - TenX Keane Acquisition (0001851484) (Subject)

SC 13G/A - TenX Keane Acquisition (0001851484) (Subject)

SC 13G - TenX Keane Acquisition (0001851484) (Subject)

SC 13G/A - TenX Keane Acquisition (0001851484) (Subject)

SC 13G/A - TenX Keane Acquisition (0001851484) (Subject)